All In Biotech

Drug Trial Radar · NCT04047862

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

446

Actual

Start

Aug 15, 2019

Primary completion

Aug 7, 2024

Study completion Aug 7, 2024

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Aug 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as ociperlimab) in combination with tislelizumab in participants with advanced solid tumors in phase 1. Primary objective of Phase 1b was to assess overall response rate (ORR) determined by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1 for patients in each dose-expansion cohort.

Conditions

  • Locally Advanced and Metastatic Solid Tumors

Interventions

  • OciperlimabDrug

    Administered as an intravenous (IV) injection

  • TislelizumabDrug

    Administered as an IV injection

  • PemetrexedDrug

    Administered in accordance with local guidelines, prescribing information/summary of product

  • PaclitaxelDrug

    Administered in accordance with local guidelines , prescribing information/summary of product

  • Nab paclitaxelDrug

    Administered in accordance with local guidelines , prescribing information/summary of product

  • CarboplatinDrug

    Administered in accordance with local guidelines , prescribing information/summary of product

  • CisplatinDrug

    Administered in accordance with local guidelines , prescribing information/summary of product

  • EtoposideDrug

    Administered in accordance with local guidelines , prescribing information/summary of product

  • 5fluorouracilDrug

    Administered in accordance with local guidelines , prescribing information/summary of product

  • OxaliplatinDrug

    Administered in accordance with local guidelines , prescribing information/summary of product

  • CapecitabineDrug

    Administered in accordance with local guidelines , prescribing information/summary of product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Up to 30 days after the last dose of study interventions (up to 35.7 months [Dose escalation cohorts] and up to 13.3 months [Dose verification cohorts])
  2. Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days (for Dose escalation cohorts) and up to 21 days (for Dose verification cohorts)
  3. Phase 1: Maximum Administered Dose (MAD) of Ociperlimab in Combination With TislelizumabTime frame: Up to 28 days (Dose escalation cohort)
  4. Phase 1: Recommended Phase 2 Dose (RP2D) of Ociperlimab in Combination With TislelizumabTime frame: up to 28 days (Dose escalation cohorts)
  5. Phase 1b: Overall Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1Time frame: Maximum time duration on study: up to 41.6 months (Cohorts 1 to 9) and up to 21.4 months (Cohort 10)

Locations

65 sites in 6 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Phoenix

    Phoenix, Arizona

  • Scri Florida Cancer Specialists South

    Fort Myers, Florida

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Scri Florida Cancer Specialists North

    St. Petersburg, Florida

  • University of Kansas Medical Center Research Institute

    Kansas City, Kansas

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Providence Portland Medical Center

    Portland, Oregon

  • Tennessee Oncology, Pllc Nashville

    Nashville, Tennessee

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia

  • Chris Obrien Lifehouse

    Camperdown, New South Wales, Australia

  • Pindara Private Hospital

    Benowa, Queensland, Australia

  • Icon Cancer Foundation

    South Brisbane, Queensland, Australia

  • Metro South Health, Cancer Trials Unit Division of Cancer Services Pah

    Woolloongabba, Queensland, Australia

  • Ashford Cancer Centre Research Northeast

    Windsor Gardens, South Australia, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Bendigo Health

    Bendigo, Victoria, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • St Vincents Hospital

    Fitzroy, Victoria, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • St John of God Health Care

    Subiaco, Western Australia, Australia

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Tongren Hospital, Cmu

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Beijing Luhe Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The First Affiliated Hospital of Xian Jiaotong University

    Xi'an, Shaanxi, China

  • Jinan Central Hospital

    Jinan, Shandong, China

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.